LOTTE BIOLOGICS Signs Antibody Manufacturing Contract with Ottimo Pharma

Published: Wednesday, June 18, 2025 at 11:00 pm

LOTTE BIOLOGICS to Manufacture Antibody Therapeutics for Ottimo Pharma

SEOUL, South Korea – LOTTE BIOLOGICS has announced a new contract manufacturing agreement with Ottimo Pharma, a biopharmaceutical company focused on developing cancer treatments. The agreement will see LOTTE BIOLOGICS produce antibody drug substance for Ottimo Pharma's Jankistomig, a novel antibody therapy.

The manufacturing will take place at LOTTE BIOLOGICS' Syracuse Bio Campus in New York. This facility currently offers contract development and manufacturing organization (CDMO) services, including cell line development and large-scale biopharmaceutical manufacturing. The company's CEO, James Park, highlighted the agreement as further validation of their competitiveness in the global antibody therapeutics market.

Ottimo Pharma's Vice President of Technical Development & Manufacturing, Joseph Shultz, emphasized the significance of the collaboration in accelerating the development of Jankistomig, supporting their path to clinical trials.

LOTTE BIOLOGICS, founded in 2022, is expanding its global presence. The company is actively partnering with biopharmaceutical companies in Asia and Europe. They are also investing in Antibody-Drug Conjugates (ADCs) services, offering end-to-end solutions from drug substance manufacturing to conjugation.

The company is also expanding its manufacturing capacity. LOTTE BIOLOGICS is constructing three bio plants in Songdo, South Korea, with the first plant expected to be operational by 2027. These plants will significantly increase the company's production volume.

BNN's Perspective:

This agreement highlights the growing importance of CDMOs in the biopharmaceutical industry. The partnership between LOTTE BIOLOGICS and Ottimo Pharma demonstrates a trend towards collaboration and specialization, which can accelerate the development of innovative therapies. While the industry faces challenges, this deal signals continued growth and investment in the sector.

Keywords: LOTTE BIOLOGICS, Ottimo Pharma, antibody therapeutics, contract manufacturing, CDMO, Jankistomig, biopharmaceutical, Syracuse Bio Campus, Songdo Bio Campus, drug substance, cancer treatment, clinical trials, biomanufacturing, ADC, antibody-drug conjugates

Full Story